Protein player

By modulating targets upstream of the ubiquitin proteasome system and inducing both stabilization and destabilization of target proteins, Third Rock Ventures believes newco Cedilla Therapeutics Inc. could have a broader reach than competing protein degradation companies. The VC launched Cedilla with a $56.2 million series A round to further build out its small molecule discovery platform.

Companies including C4 Therapeutics Inc. and Arvinas LLC are developing bifunctional molecules that link target proteins to the enzyme E3 ubiquitin ligase, which marks proteins for degradation by the proteasome. ...